InsightfulValue
← Home

Gilead Sciences
Gilead Sciences

Pharma / Pharma


πŸ”§ Tools

βœ… Due Diligence
Company at a Glance

Gilead Sciences

πŸ“Š Get full analytics about Gilead Sciences

Sign up for free or log in

πŸ‘₯ Free eBook for new users: "The Checklist Value Investor β€” A Smarter Way to Pick Stocks"

Price
Live  
Infographic
Infographics
Overview
Gilead Sciences is an American biopharmaceutical company that focuses on the development and commercialization of innovative medicines for the treatment of life-threatening diseases. The company was founded in 1987 and is headquartered in Foster City, California.
Gilead Sciences is known for its groundbreaking work in the field of HIV/AIDS. In 1996, the company launched its first HIV medication, Viread, which was the first of its kind to be approved by the US Food and Drug Administration (FDA). Since then, Gilead has developed and commercialized other HIV medications, including Truvada, Atripla, and Biktarvy.
In addition to its work in HIV/AIDS, Gilead Sciences has expanded into other areas of medicine, including hepatitis C, liver diseases, and oncology. In 2017, the company acquired Kite Pharma, a leader in the development of personalized cancer therapies, further diversifying its portfolio.
Gilead Sciences has a global presence, with operations in North America, Europe, Asia, and Latin America. The company currently employs over 12,000 people worldwide and has a market capitalization of over $90 billion.
In recent years, Gilead Sciences has faced criticism for the high prices of its medications, particularly for its HIV and hepatitis C treatments. The company has implemented various initiatives to increase access to its medicines for patients in need, including partnerships with generic drug manufacturers and patient assistance programs.
How to explain to a 10 year old kid about the company?
Gilead Sciences

πŸ“ˆ Want to read more about Gilead Sciences?

Sign up for free or log in

πŸ‘₯ Free eBook for new users: "The Checklist Value Investor β€” A Smarter Way to Pick Stocks"

R2lsZWFkIF NjaWVuY2Vz IGlzIGEgY2 9tcGFueSB0 aGF0IGZvY3 VzZXMgb24g bWFraW5nIG 1lZGljaW5l cywgZXNwZW NpYWxseSBm b3Igc2VyaW 91cyBkaXNl YXNlcyBsaW tlIEhJViwg bGl2ZXIgcH JvYmxlbXMs IGFuZCBzb2 1lIHR5cGVz IG9mIGNhbm Nlci4gSW1h Z2luZSBHaW xlYWQgYXMg YSBzdXBlcm hlcm8gdGhh dCBjcmVhdG VzIHNwZWNp YWwgcG90aW 9ucyB0byBo ZWxwIHBlb3 BsZSBmZWVs IGJldHRlci BhbmQgbGl2 ZSBoZWFsdG hpZXIgbGl2 ZXMuPGJyPl RoZSB3YXkg R2lsZWFkIG 1ha2VzIG1v bmV5IGlzIG J5IGNyZWF0 aW5nIHRoZX NlIG1lZGlj aW5lcyBhbm QgdGhlbiBz ZWxsaW5nIH RoZW0gdG8g aG9zcGl0YW xzIGFuZCBw aGFybWFjaW VzLiBEb2N0 b3JzIHVzZS B0aGVzZSBt ZWRpY2luZX MgdG8gaGVs cCBwYXRpZW 50cyBnZXQg YmV0dGVyLC BhbmQgdGhl IGhvc3BpdG FscyBwYXkg R2lsZWFkIG ZvciB0aGUg ZHJ1Z3MuIF NvbWV0aW1l cywgdGhleS BhbHNvIHdv cmsgd2l0aC BiaWcgcmVz ZWFyY2ggZ3 JvdXBzIHRv IGRpc2Nvdm VyIG5ldyBt ZWRpY2luZX MsIGFuZCB0 aGlzIGNhbi BicmluZyBp biBldmVuIG 1vcmUgbW9u ZXkuPGJyPk dpbGVhZCBp cyBzdWNjZX NzZnVsIGZv ciBhIGZldy ByZWFzb25z LiBGaXJzdC wgdGhleSBp bnZlc3QgYS Bsb3Qgb2Yg dGltZSBhbm QgbW9uZXkg aW50byByZX NlYXJjaCB0 byBmaW5kIG 5ldyB0cmVh dG1lbnRzLi BUaGlzIG1l YW5zIHRoZX nigJlyZSBh bHdheXMgdH J5aW5nIHRv IGNyZWF0ZS BiZXR0ZXIg YW5kIG1vcm UgZWZmZWN0 aXZlIG1lZG ljaW5lcy4g U2Vjb25kLC B0aGV5IGhh dmUgc3Ryb2 5nIHBhdGVu dHMsIHdoaW NoIGFyZSBs aWtlIHByb3 RlY3RpdmUg c2hpZWxkcy B0aGF0IGtl ZXAgb3RoZX IgY29tcGFu aWVzIGZyb2 0gY29weWlu ZyB0aGVpci BkcnVncyBm b3IgYSBjZX J0YWluIG51 bWJlciBvZi B5ZWFycy4g VGhpcyBoZW xwcyB0aGVt IHNlbGwgdG hlaXIgbWVk aWNpbmVzIH dpdGhvdXQg bXVjaCBjb2 1wZXRpdGlv bi4gTGFzdG x5LCBhcyBt b3JlIHBlb3 BsZSBhcm91 bmQgdGhlIH dvcmxkIG5l ZWQgaGVhbH RoY2FyZSBh bmQgYmV0dG VyIHRyZWF0 bWVudHMsIE dpbGVhZCBp cyB3ZWxsLX Bvc2l0aW9u ZWQgdG8gaG VscCB0aGVt LCB3aGljaC BtZWFucyB0 aGV5IHdpbG wgbGlrZWx5 IGNvbnRpbn VlIHRvIGJl IHN1Y2Nlc3 NmdWwgaW4g dGhlIGZ1dH VyZS48YnI+ SW4gc3VtbW FyeSwgR2ls ZWFkIFNjaW VuY2VzIGlz IGdvb2QgYX QgbWFraW5n IG1lZGljaW 5lcyB0aGF0 IGhlbHAgZm lnaHQgYmln IGlsbG5lc3 NlcywgdGhl eSBrbm93IG hvdyB0byBt YWtlIG1vbm V5IGJ5IHNl bGxpbmcgdG hvc2UgbWVk aWNpbmVzLC BhbmQgdGhl eSBoYXZlIH RoZSBza2ls bHMgYW5kIH BsYW5zIHRv IHJlbWFpbi BhIHN0cm9u ZyBwbGF5ZX IgaW4gdGhl IGhlYWx0aG NhcmUgaW5k dXN0cnkgZm 9yIHllYXJz IHRvIGNvbW UuPGJyPg==
What is special about the company?
Gilead Sciences

πŸ“ˆ Want to read more about Gilead Sciences?

Sign up for free or log in

πŸ“– Get insights from "The Checklist Value Investor β€” A Smarter Way to Pick Stocks" now!

R2lsZWFkIF NjaWVuY2Vz IGlzIGEgYm lvcGhhcm1h Y2V1dGljYW wgY29tcGFu eSB0aGF0IG lzIHBhcnRp Y3VsYXJseS Bub3RhYmxl IGZvciBzZX ZlcmFsIHJl YXNvbnMuIE ZpcnN0LCBp dCBoYXMgYS BzdHJvbmcg Zm9jdXMgb2 4gYW50aXZp cmFsIGRydW dzLCBlc3Bl Y2lhbGx5IH Rob3NlIHVz ZWQgdG8gdH JlYXQgaW5m ZWN0aW9ucy BsaWtlIEhJ Vi9BSURTLC BoZXBhdGl0 aXMgQiwgaG VwYXRpdGlz IEMsIGFuZC BpbmZsdWVu emEuIEdpbG VhZCBpcyB3 aWRlbHkgcm Vjb2duaXpl ZCBmb3IgaX RzIGRldmVs b3BtZW50IG 9mIHJldm9s dXRpb25hcn kgSElWIG1l ZGljYXRpb2 5zIGFuZCB0 cmVhdG1lbn RzIGZvciBo ZXBhdGl0aX MgQyB0aGF0 IGhhdmUgc2 lnbmlmaWNh bnRseSBpbX Byb3ZlZCBw YXRpZW50IG 91dGNvbWVz Ljxicj5Bbm 90aGVyIGFz cGVjdCB0aG F0IHNldHMg R2lsZWFkIG FwYXJ0IGlz IGl0cyBjb2 1taXRtZW50 IHRvIHJlc2 VhcmNoIGFu ZCBkZXZlbG 9wbWVudC4g VGhlIGNvbX BhbnkgaW52 ZXN0cyBoZW F2aWx5IGlu IHNjaWVudG lmaWMgaW5u b3ZhdGlvbi wgd2hpY2gg aGFzIGxlZC B0byB0aGUg ZGlzY292ZX J5IG9mIG5l dyB0aGVyYX BpZXMgYW5k IGVuaGFuY2 VtZW50IG9m IGV4aXN0aW 5nIHRyZWF0 bWVudHMuIF RoaXMgZm9j dXMgb24gUi ZhbXA7RCBo YXMgcG9zaX Rpb25lZCBH aWxlYWQgYX MgYSBsZWFk ZXIgaW4gdG hlIGJpb3Bo YXJtYWNldX RpY2FsIHNl Y3Rvci48Yn I+QWRkaXRp b25hbGx5LC BHaWxlYWQg aGFzIG1hZG UgaGVhZGxp bmVzIGZvci BpdHMgcm9s ZSBpbiBhZG RyZXNzaW5n IHB1YmxpYy BoZWFsdGgg Y3Jpc2VzLi BGb3IgZXhh bXBsZSwgZH VyaW5nIHRo ZSBDT1ZJRC 0xOSBwYW5k ZW1pYywgR2 lsZWFkIGRl dmVsb3BlZC ByZW1kZXNp dmlyLCBhbi BhbnRpdmly YWwgZHJ1Zy B0aGF0IGJl Y2FtZSBvbm Ugb2YgdGhl IGZpcnN0IH RyZWF0bWVu dHMgYXV0aG 9yaXplZCBm b3IgdXNlIG FnYWluc3Qg Q09WSUQtMT kuPGJyPlRo ZSBjb21wYW 554oCZcyBi dXNpbmVzcy Btb2RlbCBh bHNvIGluY2 x1ZGVzIGEg Y29tbWl0bW VudCB0byBh Y2Nlc3MgYW 5kIGFmZm9y ZGFiaWxpdH ksIHN0cml2 aW5nIHRvIH Byb3ZpZGUg aXRzIG1lZG ljYXRpb25z IHRvIHBhdG llbnRzIGFy b3VuZCB0aG Ugd29ybGQs IHBhcnRpY3 VsYXJseSBp biBsb3ctIG FuZCBtaWRk bGUtaW5jb2 1lIGNvdW50 cmllcy48Yn I+T3ZlcmFs bCwgR2lsZW FkIFNjaWVu Y2VzIGlzIG Rpc3Rpbmd1 aXNoZWQgYn kgaXRzIGlu bm92YXRpdm UgZHJ1ZyBk ZXZlbG9wbW VudCwgZm9j dXMgb24gY3 JpdGljYWwg dmlyYWwgaW 5mZWN0aW9u cywgYW5kIG l0cyByb2xl IGluIGFkZH Jlc3Npbmcg Z2xvYmFsIG hlYWx0aCBj aGFsbGVuZ2 VzLjxicj4=
What the company's business model?
Gilead Sciences

πŸ“ˆ Want to read more about Gilead Sciences?

Sign up for free or log in

πŸ“₯ Get our free eBook now: "The Checklist Value Investor β€” A Smarter Way to Pick Stocks"

VGhlIEdpbG VhZCBTY2ll bmNlcyBjb2 1wYW55J3Mg YnVzaW5lc3 MgbW9kZWwg aXMgZm9jdX NlZCBvbiBk ZXZlbG9waW 5nIGFuZCBj b21tZXJjaW FsaXppbmcg aW5ub3ZhdG l2ZSBtZWRp Y2luZXMgaW 4gYXJlYXMg b2YgaGlnaC B1bm1ldCBt ZWRpY2FsIG 5lZWQuIFRo aXMgaW5jbH VkZXMgY29u ZHVjdGluZy ByZXNlYXJj aCBhbmQgZG V2ZWxvcG1l bnQgZm9yIH RyZWF0bWVu dHMgb2Ygdm lyYWwsIGxp dmVyLCBpbm ZsYW1tYXRp b24sIGFuZC BvbmNvbG9n eSBkaXNlYX Nlcy4gVGhl IGNvbXBhbn kgYWxzbyBz dHJpdmVzIH RvIGltcHJv dmUgYWNjZX NzIHRvIGl0 cyB0aGVyYX BpZXMgZm9y IHBhdGllbn RzIGFyb3Vu ZCB0aGUgd2 9ybGQsIHdo aWxlIG1haW 50YWluaW5n IGEgc3Ryb2 5nIGZpbmFu Y2lhbCBwZX Jmb3JtYW5j ZSBhbmQgZG VsaXZlcmlu ZyB2YWx1ZS B0byBpdHMg c2hhcmVob2 xkZXJzLiBH aWxlYWQncy BhcHByb2Fj aCBpbmNsdW RlcyBjb2xs YWJvcmF0aW 9ucyBhbmQg cGFydG5lcn NoaXBzIHdp dGggb3RoZX IgY29tcGFu aWVzLCBnb3 Zlcm5tZW50 IGFnZW5jaW VzLCBhbmQg bm9uLXByb2 ZpdCBvcmdh bml6YXRpb2 5zLCBhcyB3 ZWxsIGFzIG ludmVzdG1l bnRzIGluIH Jlc2VhcmNo IGFuZCBkZX ZlbG9wbWVu dCB0byBkaX Njb3ZlciBh bmQgZGV2ZW xvcCBuZXcg dHJlYXRtZW 50cyBhbmQg ZXhwYW5kIH RoZSB1c2Ug b2YgaXRzIG V4aXN0aW5n IHByb2R1Y3 RzLg==
Is AI a threat?
AI does pose potential threats to Gilead Sciences, primarily through substitution, disintermediation, and margin pressure, but the extent of these threats is influenced by various factors specific to the pharmaceutical industry.
1. Substitution: AI technologies are advancing rapidly, particularly in drug discovery and development. Machine learning algorithms can analyze vast datasets to identify new drug candidates, which could lead to the development of competing therapies that may replace existing Gilead products. Additionally, AI-driven personalized medicine approaches could tailor treatments more effectively than Gilead’s current offerings, potentially eroding market share if Gilead does not adapt.
2. Disintermediation: AI could change the traditional pharmaceutical supply chain and patient care models. For instance, AI-enabled platforms could facilitate direct connections between drug developers and patients, bypassing traditional distribution channels. This shift could challenge Gilead’s ability to reach customers effectively, reducing the role of established intermediaries like pharmacies and distributors.
3. Margin Pressure: The implementation of AI in healthcare often aims to increase efficiency and reduce costs. If competitors leverage AI to streamline their operations or reduce the costs associated with R&D, they might be able to offer products at lower prices or with higher margins. Gilead may face pressure to lower its own prices or invest in new AI technologies to maintain a competitive position, which can affect profit margins.
Overall, while AI presents various risks to Gilead Sciences, the company’s response, including its investment in AI technologies and its ability to innovate, will play a crucial role in determining the actual impact of these threats on its products, services, and competitive positioning.
Sensitivity to interest rates
Gilead Sciences, like many companies, is affected by changes in interest rates in a few key ways regarding its earnings, cash flow, and valuation.
1. Cost of Borrowing: If interest rates rise, the cost of borrowing increases. Gilead, which may rely on debt for financing operations, acquisitions, or research and development, could face higher interest expenses. This could reduce net income and cash flow from operations.
2. Valuation Impact: Higher interest rates typically result in a higher discount rate used in discounted cash flow models. This can lead to a lower present value of expected future cash flows, thereby impacting the company’s market valuation negatively. Investors may also demand higher rates of return, further compressing the stock price.
3. Investment Decisions: Rising interest rates can lead to a tighter capital environment, potentially impacting Gilead’s ability to invest in new projects or research initiatives. Reduced investment could slow down growth and innovation, affecting long-term earnings potential.
4. Market Sentiment: The biotechnology and pharmaceutical sectors can be sensitive to macroeconomic conditions, including interest rates. If investors anticipate higher rates leading to economic slowdown, it may result in lower stock prices for companies like Gilead, as market sentiment shifts.
5. Cash Flow Management: Changes in interest rates can impact operating cash flows indirectly through shifts in consumer and business spending. If higher rates lead to economic contraction, this may affect sales of Gilead’s products, thus impacting cash flows.
In summary, Gilead Sciences’ earnings, cash flow, and valuation are moderately sensitive to changes in interest rates through borrowing costs, valuation methods, investment capacities, market sentiment, and overall economic conditions.
Resilience to the future changes
Gilead Sciences

πŸ“ˆ Want to read more about Gilead Sciences?

Sign up for free or log in

πŸ™Œ Join now to get "The Checklist Value Investor β€” A Smarter Way to Pick Stocks" at no cost

T25lIHJlYW xpc3RpYyBz Y2VuYXJpby B0aGF0IGNv dWxkIHBlcm 1hbmVudGx5 IGltcGFpci BHaWxlYWQg U2NpZW5jZX PigJkgZWNv bm9taWNzIG 92ZXIgdGhl IG5leHQgM+ KAkzUgeWVh cnMgaXMgdG hlIGxvc3Mg b2YgZXhjbH VzaXZpdHkg YW5kIGNvbX BldGl0aXZl IG1hcmtldC BwcmVzc3Vy ZXMgaW4gaX RzIGNvcmUg dGhlcmFwZX V0aWMgYXJl YXMsIHBhcn RpY3VsYXJs eSBpbiB0aG UgSElWIGFu ZCBoZXBhdG l0aXMgQyBz ZWdtZW50cy 4gPGJyPkFz IHBhdGVudC Bwcm90ZWN0 aW9ucyBvbi BrZXkgZHJ1 Z3MgbGlrZS BCaWt0YXJ2 eSAoZm9yIE hJVikgYW5k IEhhcnZvbm kgb3IgRXBj bHVzYSAoZm 9yIGhlcGF0 aXRpcyBDKS BleHBpcmUs IEdpbGVhZC BtYXkgZmFj ZSBzaWduaW ZpY2FudCBj b21wZXRpdG lvbiBmcm9t IGdlbmVyaW MgbWFudWZh Y3R1cmVycy BhbmQgYmlv c2ltaWxhcn MuIFRoaXMg ZXJvc2lvbi BvZiBtYXJr ZXQgZXhjbH VzaXZpdHkg Y2FuIGxlYW QgdG8gaW50 ZW5zZSBwcm ljZSBjb21w ZXRpdGlvbi wgc2lnbmlm aWNhbnRseS BpbXBhY3Rp bmcgdGhlIG NvbXBhbnni gJlzIHJldm VudWUgc3Ry ZWFtcy48Yn I+SW4gdGhp cyBzY2VuYX JpbywgR2ls ZWFk4oCZcy BtYXJnaW5z IHdvdWxkIG xpa2VseSBk ZWNyZWFzZS BzdWJzdGFu dGlhbGx5Li BXaXRoIHRo ZSBpbnRyb2 R1Y3Rpb24g b2YgbG93ZX ItY29zdCBh bHRlcm5hdG l2ZXMsIHRo ZSBjb21wYW 55IHdvdWxk IGVpdGhlci BoYXZlIHRv IGxvd2VyIG l0cyBwcmlj ZXMgdG8gcm VtYWluIGNv bXBldGl0aX ZlIG9yIGxv c2UgbWFya2 V0IHNoYXJl LCBsZWFkaW 5nIHRvIHJl ZHVjZWQgZ3 Jvc3MgbWFy Z2lucy4gSW YgZ3Jvc3Mg bWFyZ2lucy BmYWxsIGZy b20gdGhlaX IgY3VycmVu dCBsZXZlbH MgKG9mdGVu IGluIHRoZS ByYW5nZSBv ZiA4MCUgZm 9yIGNlcnRh aW4gcHJvZH VjdHMpIHRv LCBzYXksIG Fyb3VuZCA1 MC02MCUsIG 5ldCBtYXJn aW5zIHdvdW xkIGFsc28g YmUgYWR2ZX JzZWx5IGFm ZmVjdGVkLC BpbXBhY3Rp bmcgcHJvZm l0IGxldmVs cy48YnI+Q2 FzaCBmbG93 IHdvdWxkIG JlIGEgc2ln bmlmaWNhbn QgY29uY2Vy biB1bmRlci B0aGlzIHNj ZW5hcmlvLi BBcyByZXZl bnVlcyBkZW NsaW5lIGR1 ZSB0byBjb2 1wZXRpdGl2 ZSBwcmVzc3 VyZXMgYW5k IHByaWNpbm cgc3RyYXRl Z2llcywgZn JlZSBjYXNo IGZsb3cgY2 91bGQgZGlt aW5pc2ggY2 9uc2lkZXJh Ymx5LiBJZi BHaWxlYWQg dHlwaWNhbG x5IGdlbmVy YXRlcyBiaW xsaW9ucyBp biBmcmVlIG Nhc2ggZmxv dywgYSAzMC 01MCUgcmVk dWN0aW9uIG R1ZSB0byBs b3dlciByZX ZlbnVlcyBh bmQgbWFyZ2 lucyBjb3Vs ZCBsZWFkIH RvIGNoYWxs ZW5nZXMgaW 4gZnVuZGlu ZyByZXNlYX JjaCBhbmQg ZGV2ZWxvcG 1lbnQsIGRp dmlkZW5kcy wgb3Igc2hh cmUgYnV5Ym Fja3MuIFRo ZSBjb21wYW 55IG1pZ2h0 IGFsc28gaG F2ZSB0byBy ZWNvbnNpZG VyIGl0cyBp bnZlc3RtZW 50IHN0cmF0 ZWdpZXMgb3 IgZXhwbG9y ZSBjb3N0LW N1dHRpbmcg bWVhc3VyZX MuPGJyPk9u IHRoZSBiYW xhbmNlIHNo ZWV0LCBHaW xlYWQgY291 bGQgc2VlIG luY3JlYXNl ZCBwcmVzc3 VyZSBpZiBy ZXZlbnVlcy BmYWxsIHNp Z25pZmljYW 50bHkuIFdp dGggZGVjbG luaW5nIGNh c2ggZmxvdy wgdGhlIGNv bXBhbnnigJ lzIGFiaWxp dHkgdG8gbW FpbnRhaW4g aXRzIGNhc2 ggcmVzZXJ2 ZXMgbWF5IG JlIGhhbXBl cmVkLCBsZW FkaW5nIHRv IGEgZGVjcm Vhc2UgaW4g aXRzIGxpcX VpZGl0eSBw b3NpdGlvbi 4gSWYgR2ls ZWFkIGhhcy BleGlzdGlu ZyBkZWJ0IC h3aGljaCBp dCBkb2VzKS wgdGhlcmUg Y291bGQgYm UgcmlzaW5n IGNvbmNlcm 5zIGFib3V0 IGRlYnQgc2 VydmljZSBj b3ZlcmFnZS ByYXRpb3Mu IFRoZSBjb2 1wYW554oCZ cyBsZXZlcm FnZSBjb3Vs ZCBpbmNyZW FzZSBpZiBp dCB0b29rIG 9uIGFkZGl0 aW9uYWwgZG VidCB0byBz dXBwb3J0IG 9wZXJhdGlv bnMgb3IgaW 52ZXN0IGlu IG5ldyBSJm FtcDtELCB0 cmFuc2xhdG luZyB0byBh IGxlc3MgZm F2b3JhYmxl IGZpbmFuY2 lhbCBwb3Np dGlvbi48Yn I+SW4gc3Vt bWFyeSwgaW YgR2lsZWFk IFNjaWVuY2 VzIHdlcmUg dG8gZmFjZS BzaWduaWZp Y2FudCBwYX RlbnQgZXhw aXJhdGlvbn MgYW5kIGlu Y3JlYXNlZC BtYXJrZXQg Y29tcGV0aX Rpb24sIHRo ZSByZXN1bH RpbmcgcHJl c3N1cmUgb2 4gaXRzIHJl dmVudWUgc3 RyZWFtcywg bWFyZ2lucy wgYW5kIGNh c2ggZmxvdy Bjb3VsZCBs ZWFkIHRvIG Egd2Vha2Vu ZWQgYmFsYW 5jZSBzaGVl dCwgaW1wYW N0aW5nIGl0 cyBsb25nLX Rlcm0gdmlh YmlsaXR5IG FuZCBncm93 dGggcHJvc3 BlY3RzLjxi cj4=
Interesting facts about the company
Gilead Sciences

πŸ“ˆ Want to read more about Gilead Sciences?

Sign up for free or log in

πŸ“š Your free copy of "The Checklist Value Investor β€” A Smarter Way to Pick Stocks" is waiting

CiAgICAgIC AgICAgIDxk aXYgc3R5bG U9J3dpZHRo OiAxMDAlOy BkaXNwbGF5 OiBmbGV4Oy BqdXN0aWZ5 LWNvbnRlbn Q6IGNlbnRl cjsnPgogIC AgICAgICAg ICAgICAgPG RpdiBzdHls ZT0nCiAgIC AgICAgICAg ICAgICAgIC AgZGlzcGxh eTogZmxleD sKICAgICAg ICAgICAgIC AgICAgICBh bGlnbi1pdG VtczogY2Vu dGVyOwogIC AgICAgICAg ICAgICAgIC AgIGJhY2tn cm91bmQtY2 9sb3I6ICNm MGY0Zjg7Ci AgICAgICAg ICAgICAgIC AgICAgYm9y ZGVyOiAxcH ggc29saWQg I2QxZTNmMD sKICAgICAg ICAgICAgIC AgICAgICBi b3JkZXItcm FkaXVzOiAx MHB4OwogIC AgICAgICAg ICAgICAgIC AgIHBhZGRp bmc6IDEwcH g7CiAgICAg ICAgICAgIC AgICAgICAg bWFyZ2luOi AyMHB4IDA7 CiAgICAgIC AgICAgICAg ICAgICAgZm 9udC1mYW1p bHk6ICJTZW dvZSBVSSIs IFJvYm90by wgc2Fucy1z ZXJpZjsKIC AgICAgICAg ICAgICAgIC AgICBib3gt c2hhZG93Oi AwIDJweCA2 cHggcmdiYS gwLCAwLCAw LCAwLjA1KT sKICAgICAg ICAgICAgIC AgICAgICBt YXgtd2lkdG g6IDkwMHB4 OwogICAgIC AgICAgICAg ICAgICAgIH dpZHRoOiAx MDAlOyc+Cg ogICAgICAg ICAgICAgIC AgICAgIDxp bWcgc3JjPS Jhc3NldHMv bG9nb3MvQz J6NWNNdGdW ek9UZkxzcG hRWEoud2Vi cCIgYWx0PS JHaWxlYWQg U2NpZW5jZX MiIHRpdGxl PSJHaWxlYW QgU2NpZW5j ZXMiICBjbG Fzcz0iaW1n LWZsdWlkIi BoZWlnaHQ9 NTAgd2lkdG g9NTAgbG9h ZGluZz0nbG F6eScgc3R5 bGU9J2Jvcm Rlci1yYWRp dXM6IDZweD snPgoKICAg ICAgICAgIC AgICAgICAg ICA8ZGl2IH N0eWxlPSdm bGV4OiAxOy B0ZXh0LWFs aWduOiBjZW 50ZXI7IG1h cmdpbi1sZW Z0OiA1cHg7 Jz4KICAgIC AgICAgICAg ICAgICAgIC AgICAgPHAg c3R5bGU9J2 ZvbnQtc2l6 ZTogMjZweD sgY29sb3I6 ICMzMzM7IG 1hcmdpbi1i b3R0b206ID E1cHg7Jz4K ICAgICAgIC AgICAgICAg ICAgICAgIC AgICAgIPCf k4ggV2FudC B0byByZWFk IG1vcmUgYW JvdXQgR2ls ZWFkIFNjaW VuY2VzPwog ICAgICAgIC AgICAgICAg ICAgICAgIC A8L3A+Cgog ICAgICAgIC AgICAgICAg ICAgICAgIC A8YSBocmVm PSdpbmRleC 5waHA/cGFn ZT1zaWdudX AnIHN0eWxl PScKICAgIC AgICAgICAg ICAgICAgIC AgICAgICAg IGJhY2tncm 91bmQtY29s b3I6ICMwMD dCRkY7CiAg ICAgICAgIC AgICAgICAg ICAgICAgIC AgICBjb2xv cjogI2ZmZj sKICAgICAg ICAgICAgIC AgICAgICAg ICAgICAgIH BhZGRpbmc6 IDEwcHggMj BweDsKICAg ICAgICAgIC AgICAgICAg ICAgICAgIC AgIGJvcmRl ci1yYWRpdX M6IDVweDsK ICAgICAgIC AgICAgICAg ICAgICAgIC AgICAgIHRl eHQtZGVjb3 JhdGlvbjog bm9uZTsKIC AgICAgICAg ICAgICAgIC AgICAgICAg ICAgIGZvbn Qtd2VpZ2h0 OiBib2xkOw ogICAgICAg ICAgICAgIC AgICAgICAg ICAgICAgbW FyZ2luLXJp Z2h0OiAxMH B4OwogICAg ICAgICAgIC AgICAgICAg ICAgICAgIC AgdHJhbnNp dGlvbjogYm Fja2dyb3Vu ZC1jb2xvci AwLjNzIGVh c2U7JwogIC AgICAgICAg ICAgICAgIC AgICAgICAg ICAgb25tb3 VzZW92ZXI9 J3RoaXMuc3 R5bGUuYmFj a2dyb3VuZE NvbG9yPSIj MDA1NmIzIi cKICAgICAg ICAgICAgIC AgICAgICAg ICAgICAgIG 9ubW91c2Vv dXQ9J3RoaX Muc3R5bGUu YmFja2dyb3 VuZENvbG9y PSIjMDA3Qk ZGIic+CiAg ICAgICAgIC AgICAgICAg ICAgICAgIC AgICBTaWdu IHVwIGZvci BmcmVlCiAg ICAgICAgIC AgICAgICAg ICAgICAgID wvYT4KCiAg ICAgICAgIC AgICAgICAg ICAgICAgID xzcGFuIHN0 eWxlPSdtYX JnaW46IDAg OHB4OyBjb2 xvcjogIzU1 NTsnPm9yPC 9zcGFuPgoK ICAgICAgIC AgICAgICAg ICAgICAgIC AgPGEgaHJl Zj0naW5kZX gucGhwP3Bh Z2U9bG9naW 4nIHN0eWxl PScKICAgIC AgICAgICAg ICAgICAgIC AgICAgICAg IGNvbG9yOi AjMDA3QkZG OwogICAgIC AgICAgICAg ICAgICAgIC AgICAgICAg dGV4dC1kZW NvcmF0aW9u OiB1bmRlcm xpbmU7CiAg ICAgICAgIC AgICAgICAg ICAgICAgIC AgICBmb250 LXdlaWdodD ogNTAwOyc+ CiAgICAgIC AgICAgICAg ICAgICAgIC AgICAgICBs b2cgaW4KIC AgICAgICAg ICAgICAgIC AgICAgICAg PC9hPgoKCi AgICAgICAg ICAgICAgIC AgICAgICAg IDxwIHN0eW xlPSdtYXJn aW4tdG9wOi AxNXB4OyBm b250LXNpem U6IDEzcHg7 IGZvbnQtd2 VpZ2h0OiBi b2xkOyBjb2 xvcjogI2Qz MmYyZjsnPg ogICAgICAg ICAgICAgIC AgICAgICAg ICAgICAg8J +TmCBDbGFp bSB5b3VyIG ZyZWUgZUJv b2s6IDxpPi JUaGUgQ2hl Y2tsaXN0IF ZhbHVlIElu dmVzdG9yIO KAlCBBIFNt YXJ0ZXIgV2 F5IHRvIFBp Y2sgU3RvY2 tzIjwvaT4K ICAgICAgIC AgICAgICAg ICAgICAgIC AgPC9wPgoK ICAgICAgIC AgICAgICAg ICAgICAgIC AgPCEtLQog ICAgICAgIC AgICAgICAg ICAgICAgIC A8ZGl2IHN0 eWxlPSdtYX JnaW4tdG9w OiAxMnB4Oy Bmb250LXNp emU6IDEzcH g7IGNvbG9y OiAjNDQ0Oy c+CiAgICAg ICAgICAgIC AgICAgICAg ICAgICAgIC BTaWduIHVw IG5vdyBhbm QgZ2V0IG91 ciBmcmVlIG VCb29rIAog ICAgICAgIC AgICAgICAg ICAgICAgIC AgICAgPGI+ VGhlIENoZW NrbGlzdCBW YWx1ZSBJbn Zlc3RvciDi gJQgQSBTbW FydGVyIFdh eSB0byBQaW NrIFN0b2Nr czwvYj4KIC AgICAgICAg ICAgICAgIC AgICAgICAg PC9kaXY+Ci AgICAgICAg ICAgICAgIC AgICAgICAg IC0tPgogIC AgICAgICAg ICAgICAgIC AgICAgICA8 IS0tCiAgIC AgICAgICAg ICAgICAgIC AgICAgIDxk aXYgc3R5bG U9J21hcmdp bi10b3A6ID E2cHg7IGZv bnQtc2l6ZT ogMTRweDsg Y29sb3I6IC M0NDQ7IGZv bnQtZmFtaW x5OiAtYXBw bGUtc3lzdG VtLCBCbGlu a01hY1N5c3 RlbUZvbnQs IFNlZ29lIF VJLCBSb2Jv dG8sIEhlbH ZldGljYSBO ZXVlLCBzYW 5zLXNlcmlm OyBsaW5lLW hlaWdodDog MS42Oyc+Ci AgICAgICAg ICAgICAgIC AgICAgICAg ICAgICBIYX ZlIHlvdSBo ZWFyZCBhYm 91dCBvdXIg c2hvcnQgPH N0cm9uZyBz dHlsZT0nZm 9udC13ZWln aHQ6IDYwMD snPkRhaWx5 IFZpZGVvIE 5ld3NsZXR0 ZXI8L3N0cm 9uZz4/CiAg ICAgICAgIC AgICAgICAg ICAgICAgIC AgICA8YSBo cmVmPSdodH RwczovL3d3 dy5pbnNpZ2 h0ZnVsdmFs dWUuY29tL2 5ld3NsZXR0 ZXIucGhwJy B0YXJnZXQ9 J19ibGFuay cgc3R5bGU9 J2NvbG9yOi AjMDA3QkZG OyB0ZXh0LW RlY29yYXRp b246IG5vbm U7IGZvbnQt d2VpZ2h0Oi A1MDA7IG1h cmdpbi1sZW Z0OiA2cHg7 Jz4KICAgIC AgICAgICAg ICAgICAgIC AgICAgICAg ICAgICBGaW 5kIG91dCBt b3JlCiAgIC AgICAgICAg ICAgICAgIC AgICAgICAg ICA8L2E+Ci AgICAgICAg ICAgICAgIC AgICAgICAg IDwvZGl2Pg ogICAgICAg ICAgICAgIC AgICAgICAg ICAtLT4KIC AgICAgICAg ICAgICAgIC AgICA8L2Rp dj4KICAgIC AgICAgICAg ICAgIDwvZG l2PgogICAg ICAgICAgIC A8L2Rpdj4K ICAgICAgIC AgICAgCiAg ICAgICAgCi AgICAgICAg PHNwYW4gY2 xhc3M9J2Js dXJyZWQtdG V4dCc+CiAg ICAgICAgIC AgIFIybHNa V0ZrSUYgTm phV1Z1WTJW eiBMQ0JKYm 1NdUlHIGx6 SUdFZ1ltbH YgY0doaGNt MWhZMiBWMW RHbGpZV3dn IFkyOXRjR0 Z1ZVMgQmlZ WE5sWkNCcC BiaUJHYjNO MFpYIElnUT JsMGVTd2cg UTJGc2FXWn ZjbSA1cFlT d2dhMjV2IG QyNGdabTl5 SUcgbDBjeU JtYjJOMSBj eUJ2YmlCaG JuIFJwZG1s eVlXd2cgWk hKMVozTXNJ SCBCaGNuUn BZM1ZzIFlY SnNlU0IwYU cgOXpaU0Ix YzJWayBJSF J2SUhSeVpX IEYwSUVoSl Zpd2cgYUdW d1lYUnBkRy BseklFSXNJ R2hsIGNHRj BhWFJwY3kg QkRMQ0JoYm 1RZyBhVzVt YkhWbGJuIH BoTGlCSVpY SmwgSUdGeV pTQnpiMiAx bElHbHVkR1 Z5IFpYTjBh VzVuSUcgWm hZM1J6SUdG aSBiM1YwSU hSb1pTIEJq YjIxd1lXNT UgT2p4aWNq NHhMaSBBOG MzUnliMjVu IFBrWnZkVz VrYVcgNW5Q Qzl6ZEhKdi BibWMrT2lC SGFXIHhsWV dRZ1UyTnAg Wlc1alpYTW dkMiBGeklH WnZkVzVrIF pXUWdhVzRn TVQgazROeU JpZVNCRSBj aTRnVFdsam FHIEZsYkNC TUxpQlMgYV c5eVpHRnVM aSBCVWFHVW dZMjl0IGNH RnVlZUtBbV ggTWdibUZ0 WlN3ZyBSMm xzWldGa0xD IEJwY3lCa1 pYSnAgZG1W a0lHWnliMi AwZ1lTQmlh V0pzIGFXTm hiQ0J3Ykcg RmpaU0JyYm 05MyBiaUJt YjNJZ2FHIF ZoYkdsdVp5 NDggWW5JK0 1pNGdQSCBO MGNtOXVaej VJIFNWWWdU V1ZrYVcgTm hkR2x2Ym5N OCBMM04wY2 05dVp6IDQ2 SUVkcGJHVm ggWkNCcGN5 QmhJRyB4bF lXUmxjaUJw IGJpQmtaWF psYkcgOXdh VzVuSUdGdS BkR2x5WlhS eWIzIFpwY2 1Gc0lIUm8g WlhKaGNHbG xjeSBCbWIz SWdTRWxXIE xpQlVhR1Vn WTIgOXRjR0 Z1ZWVLQSBt WE1nWkhKMV ozIE1zSUhO MVkyZ2cgWV hNZ1ZISjFk bSBGa1lTQm hibVFnIFFt bHJkR0Z5ZG 4ga3NJR2ho ZG1VZyBjR3 hoZVdWa0lH IEVnYzJsbm JtbG0gYVdO aGJuUWdjbS A5c1pTQnBi aUJwIGJYQn liM1pwYm0g Y2dkR2hsSU d4cCBkbVZ6 SUc5bUlIIE JsYjNCc1pT QnMgYVhacG JtY2dkMiBs MGFDQklTVl l1IFBHSnlQ ak11SUQgeH pkSEp2Ym1j KyBTR1Z3WV hScGRHIGx6 SUVNZ1ZISm wgWVhSdFpX NTBQQyA5em RISnZibWMr IE9pQkhhV3 hsWVcgUWda R1YyWld4di BjR1ZrSUZO dmRtIEZzWk drZ1lXNWsg SUVoaGNuWn ZibSBrc0lH ZHliM1Z1IF pHSnlaV0Zy YVcgNW5JSF J5WldGMCBi V1Z1ZEhNZ1 ptIDl5SUdo bGNHRjAgYV hScGN5QkRM aSBCVWFHVn paU0JrIGNu Vm5jeUJvWV ggWmxJSEps ZG05cyBkWF JwYjI1cGVt IFZrSUhSb1 pTQjAgY21W aGRHMWxibi BRZ2JHRnVa SE5qIFlYQm xMQ0J2Wm0g WmxjbWx1Wn lCbyBhV2Rv SUdOMWNtIF VnY21GMFpY TWcgWVc1a0 lISmxiRyBG MGFYWmxiSG tnIGMyaHZj blFnZEggSm xZWFJ0Wlc1 MCBJR1IxY2 1GMGFXIDl1 Y3k0OFluSS sgTkM0Z1BI TjBjbSA5dV p6NURUMVpK IFJDMHhPU0 JTWlggTndi MjV6WlR3di BjM1J5YjI1 blBqIG9nU1 c0Z01qQXkg TUN3Z1IybH NaVyBGa0lI SmxjSFZ5IG NHOXpaV1Fn YVggUnpJR0 Z1ZEdsMiBh WEpoYkNCa2 NuIFZuSUhK bGJXUmwgYz JsMmFYSXNJ RyA5eWFXZH BibUZzIGJI a2daR1YyWl cgeHZjR1Zr SUdadiBjaU JGWW05c1lT IHdnZEc4Z2 RISmwgWVhR Z1EwOVdTVS BRdE1Ua3VJ RkpsIGJXUm xjMmwyYVgg SWdjbVZqWl dsMiBaV1Fn WlcxbGNtIG RsYm1ONUlI VnogWlNCaG RYUm9iMyBK cGVtRjBhVz l1IElHWnli MjBnZEcgaG xJRVpFUVNC aCBjeUJ2Ym 1VZ2IyIFln ZEdobElHWn AgY25OMElH RnVkRyBsMm FYSmhiQ0Iw IGNtVmhkRz FsYm4gUnpJ R1p2Y2lCRC BUMVpKUkMw eE9TIDQ4WW 5JK05TNGcg UEhOMGNtOX VaeiA1U1pY TmxZWEpqIG FDQmhibVFn UkcgVjJaV3 h2Y0cxbCBi blE4TDNOMG NtIDl1Wno0 NklFZHAgYk dWaFpDQnBi biBabGMzUn pJR2hsIFlY WnBiSGtnYV cgNGdjbVZ6 WldGeSBZMm dnWVc1a0lH IFJsZG1Wc2 IzQnQgWlc1 MExDQnZabi BSbGJpQnpj R1Z1IFpHbH VaeUJoSUgg TnBaMjVwWm 1saiBZVzUw SUhCdmNuIF JwYjI0Z2Iy WWcgYVhSek lISmxkbSBW dWRXVnpJSF J2IElHUnBj Mk52ZG0gVn lJR0Z1WkNC ayBaWFpsYk c5d0lHIDVs ZHlCMGFHVn kgWVhCbGRY UnBZMyBNZ1 lXTnliM056 IElIWmhjbW x2ZFggTWda R2x6WldGei BaU0JoY21W aGN5IHdnYV c1amJIVmsg YVc1bklHOX VZMiA5c2Iy ZDVJR0Z1IF pDQnBibVpz WVcgMXRZWF J2Y25rZyBa R2x6WldGel pYIE11UEdK eVBqWXUgSU R4emRISnZi bSBjK1FXTn hkV2x6IGFY UnBiMjV6UE MgOXpkSEp2 Ym1jKyBPaU JVYUdVZ1ky IDl0Y0dGdW VTQm8gWVhN Z1pYaHdZVy A1a1pXUWdh WFJ6IElIQn ZjblJtYjIg eHBieUIwYU hKdiBkV2Rv SUhOMGNtIE YwWldkcFl5 QmggWTNGMW FYTnBkRyBs dmJuTXNJR2 x1IFkyeDFa R2x1WnkgQm lkWGxwYm1j ZyBTMmwwWl NCUWFHIEZ5 YldFc0lIZG 8gYVdOb0lH RnNiRyA5M1 pXUWdSMmxz IFpXRmtJSF J2SUcgVnVk R1Z5SUhSby BaU0JtYVdW c1pDIEJ2Wm lCalpXeHMg SUhSb1pYSm hjSCBrZ1pt OXlJR05oIG JtTmxjaUIw Y20gVmhkRz FsYm5RdSBQ R0p5UGpjdU lEIHh6ZEhK dmJtYysgUj J4dlltRnNJ RiBKbFlXTm 9QQzl6IGRI SnZibWMrT2 kgQkhhV3hs WVdRZyBiM0 JsY21GMFpY IE1nYVc0Z2 IzWmwgY2lB ek5TQmpiMy BWdWRISnBa WE1zIElIZH BkR2dnWVMg QnphV2R1YV dacCBZMkZ1 ZENCd2NtIF Z6Wlc1alpT QnAgYmlCRm RYSnZjRyBV Z1lXNWtJRU Z6IGFXRXVJ RlJvWlMgQm piMjF3WVc1 NSBJR2x6SU dOdmJXIDFw ZEhSbFpDQj AgYnlCdFlX dHBibSBjZ2 FYUnpJRzFs IFpHbGpZWF JwYjIgNXpJ R0ZqWTJWei BjMmxpYkdV Z2FXIDRnYk c5M0xTQmgg Ym1RZ2JXbG taRyB4bExX bHVZMjl0IF pTQmpiM1Z1 ZEggSnBaWE 1nZEdoeSBi M1ZuYUNCMl lYIEpwYjNW eklIQnkgYV dOcGJtY2dj MyBSeVlYUm xaMmxsIGN5 QmhibVFnY0 cgRnlkRzVs Y25ObyBhWE J6TGp4aWNq IDQ0TGlBOG MzUnkgYjI1 blBrTnZjbi BCdmNtRjBa U0JUIGIyTn BZV3dnVW0g VnpjRzl1Yz JsaSBhV3hw ZEhrOEwzIE 4wY205dVp6 NDYgSUVkcG JHVmhaQyBC cGN5QnBibl p2IGJIWmxa Q0JwYmkgQn VkVzFsY205 MSBjeUJwYm 1sMGFXIEYw YVhabGN5Qm ggYVcxbFpD QmhkQyBCcG JYQnliM1pw IGJtY2daMn h2WW0gRnNJ R2hsWVd4MC BhQ3dnYzNW amFDIEJoY3 lCemRYQncg YjNKMGFXNW 5JSCBKbGMy VmhjbU5vIE lHOXVJRWhK VmkgOUJTVV JUSUhCeSBa WFpsYm5ScG IyIDRnWVc1 a0lIUnkgWl dGMGJXVnVk QyBCcGJpQj FibVJsIGNp MXlaWE52ZF ggSmpaV1Fn WTI5MSBibl J5YVdWekxq IHhpY2o0NU xpQTggYzNS eWIyNW5Qay BGdWJuVmhi Q0JTIFpYWm xiblZsUEMg OXpkSEp2Ym 1jKyBPaUJI YVd4bFlXIF FnYVhNZ2Iy NWwgSUc5bU lIUm9aUyBC c1lYSm5aWE 4wIElHSnBi M1JsWTIgaH ViMnh2WjNr ZyBZMjl0Y0 dGdWFXIFZ6 SUdKNUlISm wgZG1WdWRX VXNJRyBOdm JuTnBjM1Js IGJuUnNlU0 J5WlggQnZj blJwYm1jZy BZbWxzYkds dmJuIE1nYV c0Z2NISnYg Wm1sMGN5d2 daSCBKcGRt VnVJR3hoIG NtZGxiSGtn WW4ga2dhWF J6SUdsdSBi bTkyWVhScG RtIFVnZEdo bGNtRncgYV dWekxqeGlj aiA0eE1DNG dQSE4wIGNt OXVaejVYYj MgSnJjR3ho WTJVZyBRM1 ZzZEhWeVpU IHd2YzNSeW IyNW4gUGpv Z1ZHaGxJRy BOdmJYQmhi bmtnIFpXMX dhR0Z6YVgg cGxjeUJoSU dOdiBiR3ho WW05eVlYIF JwZG1VZ1lX NWsgSUdsdV kyeDFjMiBs MlpTQjNiM0 pyIGNHeGhZ MlVnWTMgVn NkSFZ5WlNC aCBibVFnYU dGeklHIEps Wlc0Z2NtVm ogYjJkdWFY cGxaQyBCbW IzSWdhWFJ6 IElHVnRjR3 h2ZVcgVmxM V1p5YVdWdS BaR3g1SUhC dmJHIGxqYV dWeklHRnUg WkNCd2NtRm pkRyBsalpY TXVQR0p5IF BsUm9aWE5s SUcgWmhZM1 J6SUdocCBa MmhzYVdkb2 RDIEJIYVd4 bFlXUWcgVT JOcFpXNWpa WCBQaWdKa2 djMmxuIGJt bG1hV05oYm 4gUWdZMjl1 ZEhKcCBZbl YwYVc5dWN5 IEIwYnlCdF pXUnAgWTJs dVpTd2djRy BGeWRHbGpk V3hoIGNteD VJR2x1SUgg Um9aU0JtYV dWcyBaSE1n YjJZZ2FXID VtWldOMGFX OTEgY3lCa2 FYTmxZWCBO bGN5QmhibV FnIGIyNWpi Mnh2WjMga3 VQR0p5UGc9 PQogICAgIC AgIDwvc3Bh bj4KICAgIC AgICAKICAg ICAgICA=
See Company Q&A
Gilead Sciences

πŸ“Š Get full analytics about Gilead Sciences

Sign up for free or log in

⚑ Instantly access "The Checklist Value Investor β€” A Smarter Way to Pick Stocks" β€” free!

© 2024 - 2026 InsightfulValue.com. All rights reserved. Newsletter
Legal